By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ThromboGenics Ltd. 

1560 Broadway
10th Floor
Dublin  New York  10036  New York
Phone: 212-201-0920 Fax: 212-201-0921

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease, and cancer. Our lead product, ocriplasmin (microplasmin), has completed two successful Phase III clinical trials for the pharmacological treatment of symptomatic vitreomacular adhesion (sVMA). ThromboGenics will commercialize this product via its own dedicated sales force in the United States and in Europe.

In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (anti-Factor VIII), a long-acting anticoagulant in Phase II, and TB-403 (anti-PlGF) in Phase Ib/II for cancer, in partnership with Roche.

ThromboGenics currently has around 80 employees at its headquarters in Leuven, Belgium, and at its facilities in Ireland and the United States. The Company is listed on Eurolist by Euronext Brussels under the symbol THR.

Key Statistics

Ownership: Public

Web Site: ThromboGenics Ltd.
Employees: 80
Symbol: THR.BR


Company News
BioInvent (BOVNF) Announces Plan To Initiate Clinical Development Of TB-403 In Pediatric Cancer Together With ThromboGenics Ltd. (THR.BR) 3/17/2015 11:04:25 AM
ThromboGenics Ltd. (THR.BR)' JETREA® Available in Germany Public and Private Market 5/2/2013 9:30:21 AM
ThromboGenics Ltd. (THR.BR)' JETREA®, the First and Only Medicine for Treating Vitreomacular Traction, Now Launched in the UK 4/11/2013 10:18:26 AM
ThromboGenics Ltd. (THR.BR) Starts Trading as Part of the BEL20 Index Today 3/18/2013 9:43:56 AM
ThromboGenics Ltd. (THR.BR) Transparency Declaration 7/13/2012 10:45:21 AM
ThromboGenics Ltd. (THR.BR) Receives Notice From FDA of Advisory Committee Meeting for Ocriplasmin 6/7/2012 10:42:37 AM
ThromboGenics Ltd. (THR.BR) Announces That the FDA Intends to Grant Ocriplasmin Priority Review 2/2/2012 9:46:32 AM
ThromboGenics Ltd. (THR.BR) and BioInvent Complete Enrollment of Phase IIb Trial With TB-402 Ahead of Schedule 12/16/2011 10:29:14 AM
ThromboGenics Ltd. (THR.BR) and BioInvent Complete Enrolment of Phase IIb Trial with TB-402 Ahead of Schedule 12/16/2011 7:20:56 AM
ThromboGenics Ltd. (THR.BR) Hopes for Eye Treatment Launch in 2012 8/25/2011 8:07:15 AM